{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T23:00:37Z","timestamp":1747090837214,"version":"3.37.3"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40263-017-0479-z","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T15:54:34Z","timestamp":1512575674000},"page":"939-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dispensability of Annual Laboratory Follow-Up After More than 2\u00a0Years of Valproic Acid Use: A Systematic Review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8930","authenticated-orcid":false,"given":"Rosanne W.","family":"Meijboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen P.","family":"Grootens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"issue":"6","key":"479_CR1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1399-5618.2009.00737.x","volume":"11","author":"F Ng","year":"2009","unstructured":"Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, Beaulieu S, Yatham LN, Berk M, International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559\u201395.","journal-title":"Bipolar Disord."},{"key":"479_CR2","unstructured":"NICE guideline. Bipolar disorder: assessment and management. https:\/\/www.nice.org.uk\/guidance\/cg185\/chapter\/1-Recommendations#how-to-use-medication . Accessed 31 May 2017."},{"issue":"6","key":"479_CR3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495\u2013553.","journal-title":"J Psychopharmacol."},{"key":"479_CR4","first-page":"167","volume-title":"Multidisciplinaire richtlijn bipolaire stoornissen","author":"R Kupka","year":"2015","unstructured":"Kupka R, Goossens P, van Bendegem M, Daemen P, Daggenvoorde T, Daniels M, Dols A, Hillegers M, Hoogelander A, ter Kulve E, Peetoom T, Schulte R, Stevens A, van Duine D. Multidisciplinaire richtlijn bipolaire stoornissen. Utrecht: De Tijdstroom; 2015. p. 167\u201373."},{"key":"479_CR5","unstructured":"NICE guideline. Epilepsies: diagnosis and management. https:\/\/www.nice.org.uk\/guidance\/cg137 . Accessed 28 Jun 2017."},{"issue":"1","key":"479_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O\u2019Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1\u201344.","journal-title":"Bipolar Disord."},{"issue":"2","key":"479_CR7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0887-8994(85)90046-3","volume":"1","author":"GM Fenichel","year":"1985","unstructured":"Fenichel GM, Greene HL. Valproate hepatotoxicity: two new cases, a summary of others, and recommendations. Pediatr Neurol. 1985;1(2):109\u201313.","journal-title":"Pediatr Neurol."},{"issue":"2","key":"479_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1211\/jpp.60.2.0017","volume":"60","author":"S Goto","year":"2008","unstructured":"Goto S, Seo T, Hagiwara T, et al. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients. J Pharm Pharmacol. 2008;60(2):267\u201372.","journal-title":"J Pharm Pharmacol."},{"issue":"1","key":"479_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/8755122514550490","volume":"31","author":"C Cimino","year":"2015","unstructured":"Cimino C, Charneski L, Kumar L. Idiosyncratic valproic acid-induced hepatotoxicity in a sickle cell patient. J Pharm Technol. 2015;31(1):43\u20134.","journal-title":"J Pharm Technol."},{"issue":"5","key":"479_CR10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0735-6757(97)90195-9","volume":"15","author":"R Pinkston","year":"1997","unstructured":"Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. Am J Emerg Med. 1997;15(5):504\u20136.","journal-title":"Am J Emerg Med."},{"key":"479_CR11","unstructured":"SSPC Depakote product information. https:\/\/www.medicines.org.uk\/emc\/medicine\/25929 . Accessed 16 May 2017."},{"issue":"339","key":"479_CR12","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"21","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21(339):b2535.","journal-title":"BMJ."},{"issue":"2","key":"479_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-8981(98)00094-1","volume":"276","author":"I Cepelak","year":"1998","unstructured":"Cepelak I, Zani\u0107 Grubisi\u0107 T, Mandusi\u0107 A, Reki\u0107 B, Lenicek J. Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children. Clin Chim Acta. 1998;276(2):121\u20137.","journal-title":"Clin Chim Acta."},{"issue":"8","key":"479_CR14","doi-asserted-by":"crossref","first-page":"e1002058","DOI":"10.1371\/journal.pmed.1002058","volume":"13","author":"JF Hayes","year":"2016","unstructured":"Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016;13(8):e1002058.","journal-title":"PLoS Med."},{"issue":"11","key":"479_CR15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/088307389901401114","volume":"14","author":"C Hemingway","year":"1999","unstructured":"Hemingway C, Leary M, Riordan G, Schlegal B, Walker K. The effect of carbamazepine and sodium valproate on the blood and serum values of children from a third-world environment. J Child Neurol. 1999;14(11):751\u20133.","journal-title":"J Child Neurol."},{"issue":"3","key":"479_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/wnf.0b013e3180318a99","volume":"30","author":"A Attilakos","year":"2007","unstructured":"Attilakos A, Voudris KA, Katsarou E, Prassouli A, Mastroyianni S, Garoufi A. Transient decrease in serum albumin concentrations in epileptic children treated with sodium valproate monotherapy. Clin Neuropharmacol. 2007;30(3):145\u20139.","journal-title":"Clin Neuropharmacol."},{"issue":"3","key":"479_CR17","first-page":"33","volume":"4","author":"MR Salehiomran","year":"2010","unstructured":"Salehiomran MR, Hosseini SE. The effect of anticonvulsant drugs (phenobarbital and valproic acid) on the serum level of cholesterol, triglyceride, lipoprotein and liver enzymes in convulsive children. Iran J Child Neurol. 2010;4(3):33\u20138.","journal-title":"Iran J Child Neurol."},{"issue":"3","key":"479_CR18","first-page":"305","volume":"39","author":"S Jha","year":"1995","unstructured":"Jha S, Agarwal DK, Shukla S, Nag D, Saxena RC. Hepatic functions in epileptics on sodium valproate monotherapy. Indian J Physiol Pharmacol. 1995;39(3):305\u20136.","journal-title":"Indian J Physiol Pharmacol."},{"issue":"5","key":"479_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/YIC.0000000000000084","volume":"30","author":"M Amitai","year":"2015","unstructured":"Amitai M, Sachs E, Zivony A, Remez R, Ben Baruch R, Amit BH, Kronenberg S, Apter A, Shoval G, Weizman A, Zalsman G. Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study. Int Clin Psychopharmacol. 2015;30(5):241\u20138.","journal-title":"Int Clin Psychopharmacol."},{"issue":"9","key":"479_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.braindev.2006.03.009","volume":"28","author":"M Ugras","year":"2006","unstructured":"Ugras M, Yakinci C. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Brain Dev. 2006;28(9):549\u201353.","journal-title":"Brain Dev."},{"issue":"2","key":"479_CR21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2009.03.005","volume":"41","author":"RA Lenz","year":"2009","unstructured":"Lenz RA, Elterman RD, Robieson WZ, Vigna NV, Saltarelli MD. Divalproex sodium in children with partial seizures: 12-month safety study. Pediatr Neurol. 2009;41(2):101\u201310.","journal-title":"Pediatr Neurol."},{"issue":"2","key":"479_CR22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0387-7604(95)00139-5","volume":"18","author":"E Hauser","year":"1996","unstructured":"Hauser E, Seidl R, Freilinger M, Male C, Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996;18(2):105\u20139.","journal-title":"Brain Dev."},{"issue":"2","key":"479_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0887-8994(00)00175-2","volume":"23","author":"S Demircio\u011flu","year":"2000","unstructured":"Demircio\u011flu S, Soylu A, Dirik E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol. 2000;23(2):142\u20136.","journal-title":"Pediatr Neurol."},{"key":"479_CR24","first-page":"192","volume":"19","author":"SF Berkovic","year":"1983","unstructured":"Berkovic SF, Bladin PF, Jones DB, Smallwood RA, Vajda FJ. Hepatotoxicity of sodium valproate. Clin Exp Neurol. 1983;19:192\u20137.","journal-title":"Clin Exp Neurol."},{"issue":"1","key":"479_CR25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0041-1345(99)00936-7","volume":"32","author":"MA Thomson","year":"2000","unstructured":"Thomson MA, Lynch S, Strong R, Shepherd RW, Marsh W. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate. Transplant Proc. 2000;32(1):200\u20133.","journal-title":"Transplant Proc."},{"issue":"5","key":"479_CR26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0953-6205(03)00104-3","volume":"14","author":"A Romero-Falc\u00f3n","year":"2003","unstructured":"Romero-Falc\u00f3n A, de la Santa-Belda E, Garc\u00eda-Contreras R, Varela JM. A case of valproate-associated hepatotoxicity treated with L-carnitine. Eur J Intern Med. 2003;14(5):338\u201340.","journal-title":"Eur J Intern Med."},{"issue":"3","key":"479_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(00)00151-0","volume":"41","author":"DB McLaughlin","year":"2000","unstructured":"McLaughlin DB, Eadie MJ, Parker-Scott SL, Addison RS, Henderson RD, Hooper WD, Dickinson RG. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. Epilepsy Res. 2000;41(3):259\u201368.","journal-title":"Epilepsy Res."},{"issue":"6","key":"479_CR28","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/00005176-198611000-00032","volume":"5","author":"RB Colletti","year":"1986","unstructured":"Colletti RB, Trainer TD, Krawisz BR. Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr. 1986;5(6):990\u20134.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"5","key":"479_CR29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/PEC.0b013e31828ec2d5","volume":"29","author":"A Yaman","year":"2013","unstructured":"Yaman A, Kendirli T, Odek C, Bekta\u015f O, Kulo\u011flu Z, Kolo\u011flu M, Ince E, Deda G. Valproic acid-induced acute pancreatitis and multiorgan failure in a child. Pediatr Emerg Care. 2013;29(5):659\u201361.","journal-title":"Pediatr Emerg Care."},{"issue":"7","key":"479_CR30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1752-1947-7-144","volume":"31","author":"S Mettananda","year":"2013","unstructured":"Mettananda S, Fernando AD, Ginige N. Posterior reversible encephalopathy syndrome in a survivor of valproate-induced acute liver failure: a case report. J Med Case Rep. 2013;31(7):144.","journal-title":"J Med Case Rep."},{"issue":"1","key":"479_CR31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gut.37.1.140","volume":"37","author":"S Kr\u00e4henb\u00fchl","year":"1995","unstructured":"Kr\u00e4henb\u00fchl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut. 1995;37(1):140\u20133.","journal-title":"Gut."},{"issue":"7","key":"479_CR32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1528-1157.1999.tb00814.x","volume":"40","author":"SA K\u00f6nig","year":"1999","unstructured":"K\u00f6nig SA, Schenk M, Sick C, Holm E, Heubner C, Weiss A, K\u00f6nig I, Hehlmann R. Fatal liver failure associated with valproate therapy in a patient with Friedreich\u2019s disease: review of valproate hepatotoxicity in adults. Epilepsia. 1999;40(7):1036\u201340.","journal-title":"Epilepsia."},{"issue":"2","key":"479_CR33","first-page":"133","volume":"153","author":"B Chabrol","year":"1994","unstructured":"Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr. 1994;153(2):133\u20135.","journal-title":"Eur J Pediatr."},{"issue":"2","key":"479_CR34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1067\/S0190-9622(03)00748-5","volume":"49","author":"YL Huang","year":"2003","unstructured":"Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003;49(2):316\u20139.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"479_CR35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.psym.2013.10.006","volume":"55","author":"S Rej","year":"2014","unstructured":"Rej S, Chen T, Edwards M, Zicherman V. Fulminant hepatic failure in the context of reinstituting valproate use. Psychosomatics. 2014;55(3):303\u20134.","journal-title":"Psychosomatics."},{"issue":"1","key":"479_CR36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/106002809202600104","volume":"26","author":"EA Bell","year":"1992","unstructured":"Bell EA, Shaefer MS, Markin RS, Wood RP, Langnas AN, Stratta RJ, Shaw BW Jr. Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation. Ann Pharmacother. 1992;26(1):18\u201321.","journal-title":"Ann Pharmacother."},{"issue":"12","key":"479_CR37","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1528-1167.2006.00846.x","volume":"47","author":"SA Koenig","year":"2006","unstructured":"Koenig SA, Buesing D, Longin E, Oehring R, H\u00e4ussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Br\u00fcckner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, M\u00fcller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia. 2006;47(12):2027\u201331.","journal-title":"Epilepsia."},{"issue":"3","key":"479_CR38","first-page":"155","volume":"70","author":"MA Zoelen van","year":"2012","unstructured":"van Zoelen MA, de Graaf M, van Dijk MR, Bogte A, van Erpecum KJ, Rockmann H, Maarschalk-Ellerbroek LJ. Valproic acid-induced DRESS syndrome with acute liver failure. Neth J Med. 2012;70(3):155.","journal-title":"Neth J Med."},{"issue":"1","key":"479_CR39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1176\/appi.ajp.162.1.192","volume":"162","author":"MS Bauer","year":"2005","unstructured":"Bauer MS. Fatal hepatic failure and valproate. Am J Psychiatry. 2005;162(1):192.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"479_CR40","first-page":"207","volume":"31","author":"AS Puri","year":"1994","unstructured":"Puri AS, Sharma BC, Khan EM, Saraswat VA. Fatal fulminant hepatic failure due to sodium valproate in an adolescent. Indian Pediatr. 1994;31(2):207\u201310.","journal-title":"Indian Pediatr."},{"issue":"6","key":"479_CR41","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/WNL.47.6.1608","volume":"47","author":"J Parra","year":"1996","unstructured":"Parra J, Iriarte J, Pierre-Louis SJ. Valproate toxicity. Neurology. 1996;47(6):1608.","journal-title":"Neurology."},{"issue":"5","key":"479_CR42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0030-1254125","volume":"43","author":"MM Schmid","year":"2010","unstructured":"Schmid MM, Connemann BJ, Wolf RC, Flechtenmacher C, Eisenbach C, Sch\u00f6nfeldt-Lecuona C. Can we prevent fatal liver failure under valproate? Pharmacopsychiatry. 2010;43(5):198\u2013200.","journal-title":"Pharmacopsychiatry."},{"issue":"6","key":"479_CR43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/MJT.0b013e3182053ef2","volume":"19","author":"KH Chaudrey","year":"2012","unstructured":"Chaudrey KH, Naser TB, Steinberg A, Avashia KD, Nouri-Kolouri M, Asadi S, Irshad Khan SI, Ihsan M. Thinking beyond the obvious: hepatotoxicity secondary to idiosyncratic depakote toxicity. Am J Ther. 2012;19(6):403\u20136.","journal-title":"Am J Ther."},{"issue":"2","key":"479_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-2008-1052461","volume":"18","author":"H Egmond van","year":"1987","unstructured":"van Egmond H, Degomme P, de Simpel H, Dierick AM, Roels H. A suspected case of late-onset sodium-valproate-induced hepatic failure. Neuropediatrics. 1987;18(2):96\u20138.","journal-title":"Neuropediatrics."},{"key":"479_CR45","first-page":"79","volume":"21","author":"RG Dickinson","year":"1985","unstructured":"Dickinson RG, Bassett ML, Searle J, Tyrer JH, Eadie MJ. Valproate hepatotoxicity: a review and report of two instances in adults. Clin Exp Neurol. 1985;21:79\u201391.","journal-title":"Clin Exp Neurol."},{"issue":"11","key":"479_CR46","first-page":"875","volume":"77","author":"S Itoh","year":"1982","unstructured":"Itoh S, Yamaba Y, Matsuo S, Saka M, Ichinoe A. Sodium valproate-induced liver injury. Am J Gastroenterol. 1982;77(11):875\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"479_CR47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2007.04.003","volume":"16","author":"T Gerstner","year":"2007","unstructured":"Gerstner T, Bauer MO, Longin E, Bell N, Koenig SA. Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2-year-old girl. Seizure. 2007;16(6):554\u20136.","journal-title":"Seizure."},{"issue":"1","key":"479_CR48","first-page":"24","volume":"26","author":"M Bostancioglu","year":"2009","unstructured":"Bostancioglu M, Oner N, Kucukugurluoglu Y, Kaya M, Aladag N, Celtik C, Karasalihoglu S. Does valproate therapy decrease the bone mineral density in one-year follow-up in children? Trakya Univ Med Fak Derg. 2009;26(1):24\u20138.","journal-title":"Trakya Univ Med Fak Derg."},{"issue":"4","key":"479_CR49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2004.03.021","volume":"31","author":"C Ecevit","year":"2004","unstructured":"Ecevit C, Aydo\u011fan A, Kavakli T, Altin\u00f6z S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol. 2004;31(4):279\u201382.","journal-title":"Pediatr Neurol."},{"issue":"8","key":"479_CR50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1440-1754.2004.00431.x","volume":"40","author":"N Oner","year":"2004","unstructured":"Oner N, Kaya M, Karasaliho\u011flu S, Karaca H, Celtik C, T\u00fct\u00fcnc\u00fcler F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health. 2004;40(8):470\u20133.","journal-title":"J Paediatr Child Health."},{"issue":"5","key":"479_CR51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0887-8994(03)00310-2","volume":"29","author":"TA Rugino","year":"2003","unstructured":"Rugino TA, Janvier YM, Baunach JM, Bilat CA. Hypoalbuminemia with valproic acid administration. Pediatr Neurol. 2003;29(5):440\u20134.","journal-title":"Pediatr Neurol."},{"issue":"2","key":"479_CR52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1468-1331.2009.02773.x","volume":"17","author":"A Verrotti","year":"2010","unstructured":"Verrotti A, Agostinelli S, Coppola G, Parisi P, Chiarelli F. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol. 2010;17(2):232\u20137.","journal-title":"Eur J Neurol."},{"issue":"4","key":"479_CR53","first-page":"338","volume":"18","author":"M Zare","year":"2013","unstructured":"Zare M, Ghazvini MR, Dashti M, Najafi MR, Alavi-Naeini AM. Bone turnover markers in epileptic patients under chronic valproate therapy. J Res Med Sci. 2013;18(4):338\u201340.","journal-title":"J Res Med Sci."},{"issue":"11","key":"479_CR54","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/00207450290158269","volume":"112","author":"H Caksen","year":"2002","unstructured":"Caksen H, D\u00fclger H, Cesur Y, Odaba\u015f D, Tuncer O, Ata\u015f B. No effect of long-term valproate therapy on thyroid and parathyroid functions in children. Int J Neurosci. 2002;112(11):1371\u20134.","journal-title":"Int J Neurosci."},{"issue":"1\u20132","key":"479_CR55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2009.12.015","volume":"290","author":"N Triantafyllou","year":"2010","unstructured":"Triantafyllou N, Lambrinoudaki I, Armeni E, Evangelopoulos EM, Boufidou F, Antoniou A, Tsivgoulis G. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci. 2010;290(1\u20132):131\u20134.","journal-title":"J Neurol Sci."},{"issue":"1","key":"479_CR56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ndt\/gfm682","volume":"23","author":"N Bavbek","year":"2008","unstructured":"Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A. Hyponatremia associated with sodium valproate in a 22-year-old male. Nephrol Dial Transplant. 2008;23(1):410.","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"479_CR57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/11318950-000000000-00000","volume":"33","author":"E Beers","year":"2010","unstructured":"Beers E, van Puijenbroek EP, Bartelink IH, van der Linden CM, Jansen PA. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic acid: four case reports from the Netherlands and a case\/non-case analysis of vigibase. Drug Saf. 2010;33(1):47\u201355.","journal-title":"Drug Saf."},{"issue":"2","key":"479_CR58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ana.410430219","volume":"43","author":"AJ Branten","year":"1998","unstructured":"Branten AJ, Wetzels JF, Weber AM, Koene RA. Hyponatremia due to sodium valproate. Ann Neurol. 1998;43(2):265\u20137.","journal-title":"Ann Neurol."},{"issue":"4","key":"479_CR59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000510","volume":"36","author":"YC Kuo","year":"2016","unstructured":"Kuo YC, Lin YC, Chen PH. Emerging hyperkalemia following valproic acid use in an elderly patient with late-onset mania. J Clin Psychopharmacol. 2016;36(4):394\u20135.","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"479_CR60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-200101000-00008","volume":"16","author":"T Miyaoka","year":"2001","unstructured":"Miyaoka T, Seno H, Itoga M, Kishi T, Ishino H, Horiguchi J. Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone. Int Clin Psychopharmacol. 2001;16(1):59\u201361.","journal-title":"Int Clin Psychopharmacol."},{"issue":"5","key":"479_CR61","first-page":"e1","volume":"12","author":"KR Patel","year":"2010","unstructured":"Patel KR, Meesala A, Stanilla JK. Sodium valproate-induced hyponatremia: a case report. Prim Care Companion J Clin Psychiatry. 2010;12(5):e1.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"issue":"11","key":"479_CR62","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1592\/phco.21.17.1325.34418","volume":"21","author":"EL Conley","year":"2001","unstructured":"Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21(11):1325\u201330.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"479_CR63","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1528-1157.1993.tb02139.x","volume":"34","author":"RB May","year":"1993","unstructured":"May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia. 1993;34(6):1098\u2013101.","journal-title":"Epilepsia."},{"issue":"1","key":"479_CR64","first-page":"24","volume":"9","author":"M Nasrullah","year":"2015","unstructured":"Nasrullah M, Saleem K, Zaheer M, Bhatty AF, Shafiq F. Thrombocytopenia in epileptic patients on valproic acid. PJMHS. 2015;9(1):24\u20135.","journal-title":"PJMHS."},{"issue":"1","key":"479_CR65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1176\/appi.ajp.158.1.128","volume":"158","author":"TJ Trannel","year":"2001","unstructured":"Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001;158(1):128\u201330.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"479_CR66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/088307389400900318","volume":"9","author":"MR Delgado","year":"1994","unstructured":"Delgado MR, Riela AR, Mills J, Browne R, Roach ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol. 1994;9(3):311\u20134.","journal-title":"J Child Neurol."},{"issue":"1","key":"479_CR67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/088307380201700110","volume":"17","author":"G Serdaroglu","year":"2002","unstructured":"Serdaroglu G, T\u00fct\u00fcnc\u00fcoglu S, Kavakli K, Tekg\u00fcl H. Coagulation abnormalities and acquired von Willebrand\u2019s disease type 1 in children receiving valproic acid. J Child Neurol. 2002;17(1):41\u20133.","journal-title":"J Child Neurol."},{"issue":"3","key":"479_CR68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JCP.0b013e3181db2684","volume":"30","author":"K Vasudev","year":"2010","unstructured":"Vasudev K, Keown P, Gibb I, McAllister-Williams RH. Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol. 2010;30(3):282\u20135.","journal-title":"J Clin Psychopharmacol."},{"issue":"4","key":"479_CR69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0887-8994(96)00052-5","volume":"14","author":"IN Allarakhia","year":"1996","unstructured":"Allarakhia IN, Garofalo EA, Komarynski MA, Robertson PL. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study. Pediatr Neurol. 1996;14(4):303\u20137.","journal-title":"Pediatr Neurol."},{"issue":"5","key":"479_CR70","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.jcp.0000088911.24613.0d","volume":"23","author":"D Berardis De","year":"2003","unstructured":"De Berardis D, Campanella D, Matera V, Gambi F, La Rovere R, Sepede G, Grimaldi MR, Pacilli AM, Salerno RM, Ferro FM. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol. 2003;23(5):451\u20138.","journal-title":"J Clin Psychopharmacol."},{"key":"479_CR71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0011-393X(01)80042-4","volume":"62","author":"PN Tariot","year":"2001","unstructured":"Tariot PN, Schneider LS, Mintzer JE, Cutler AJ, Cunningham MR, Thomas JW, Sommerville KW. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr Ther Res. 2001;62:51\u201367.","journal-title":"Curr Ther Res."},{"issue":"1","key":"479_CR72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1528-1167.2007.00978_1.x","volume":"48","author":"A Attilakos","year":"2007","unstructured":"Attilakos A, Katsarou E, Voudris K, Garoufi A. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2007;48(1):205\u20136.","journal-title":"Epilepsia."},{"issue":"2","key":"479_CR73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1528-1157.1999.tb02073.x","volume":"40","author":"JA Zeller","year":"1999","unstructured":"Zeller JA, Schlesinger S, Runge U, Kessler C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia. 1999;40(2):186\u20139.","journal-title":"Epilepsia."},{"issue":"8","key":"479_CR74","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.44.8.1418","volume":"44","author":"B Gidal","year":"1994","unstructured":"Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Collins M, Jones J. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology. 1994;44(8):1418\u201322.","journal-title":"Neurology."},{"issue":"1","key":"479_CR75","first-page":"15","volume":"7","author":"CH Ko","year":"2001","unstructured":"Ko CH, Kong CK, Tse PW. Valproic acid and thrombocytopenia: cross-sectional study. Hong Kong Med J. 2001;7(1):15\u201321.","journal-title":"Hong Kong Med J."},{"issue":"5","key":"479_CR76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","volume":"19","author":"S Koenig","year":"2008","unstructured":"Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis. 2008;19(5):375\u201382.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"3","key":"479_CR77","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","volume":"49","author":"W Nasreddine","year":"2008","unstructured":"Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438\u201345.","journal-title":"Epilepsia."},{"issue":"3","key":"479_CR78","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0887-8994(99)00060-0","volume":"21","author":"A Verrotti","year":"1999","unstructured":"Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol. 1999;21(3):611\u20134.","journal-title":"Pediatr Neurol."},{"issue":"3","key":"479_CR79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.152.3.413","volume":"152","author":"M Tohen","year":"1995","unstructured":"Tohen M, Castillo J, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995;152(3):413\u20138.","journal-title":"Am J Psychiatry."},{"issue":"5","key":"479_CR80","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1345\/aph.1L617","volume":"43","author":"A Rahman","year":"2009","unstructured":"Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009;43(5):822\u201330.","journal-title":"Ann Pharmacother."},{"issue":"2","key":"479_CR81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.apmr.2015.09.004","volume":"97","author":"HJ Park","year":"2016","unstructured":"Park HJ, Kim JY. Incidence of neutropenia with valproate and quetiapine combination treatment in subjects with acquired brain injuries. Arch Phys Med Rehabil. 2016;97(2):183\u20138.","journal-title":"Arch Phys Med Rehabil."},{"issue":"2","key":"479_CR82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5455\/jmood.20150420074935","volume":"5","author":"I Taymur","year":"2015","unstructured":"Taymur I, Sar\u0131 S, G\u00fcng\u00f6r B, \u0130nel A, Da\u011fl\u0131 O. A case of thrombocytopenia and anemia due to use of valproic acid. J Mood Disord. 2015;5(2):88\u20139.","journal-title":"J Mood Disord."},{"key":"479_CR83","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13l01526","author":"CS Nerumalla","year":"2013","unstructured":"Nerumalla CS, Shah AA. A case of thrombocytopenia associated with valproic acid treatment. Prim Care Companion CNS Disord. 2013;. https:\/\/doi.org\/10.4088\/PCC.13l01526 .","journal-title":"Prim Care Companion CNS Disord."},{"issue":"4","key":"479_CR84","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.psym.2014.02.007","volume":"56","author":"YT Tseng","year":"2015","unstructured":"Tseng YT, Ho PS, Wang CF, Liang CS. Valproic acid-induced thrombocytopenia may cause wound nonhealing in individuals with schizophrenia. Psychosomatics. 2015;56(4):410\u20133.","journal-title":"Psychosomatics."},{"issue":"3","key":"479_CR85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4088\/JCP.v58n0307d","volume":"58","author":"RG Fawcett","year":"1997","unstructured":"Fawcett RG. Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder. J Clin Psychiatry. 1997;58(3):125.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"479_CR86","first-page":"358","volume":"126","author":"LM Hoffman","year":"1982","unstructured":"Hoffman LM. Sodium valproate and thrombocytopenia. Can Med Assoc J. 1982;126(4):358\u20139.","journal-title":"Can Med Assoc J."},{"issue":"6","key":"479_CR87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/10245330701562428","volume":"12","author":"RW Allan","year":"2007","unstructured":"Allan RW. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature. Hematology. 2007;12(6):493\u20136.","journal-title":"Hematology."},{"issue":"10","key":"479_CR88","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/00004583-200010000-00003","volume":"39","author":"DD Storch","year":"2000","unstructured":"Storch DD. Severe leukopenia with valproate. J Am Acad Child Adolesc Psychiatry. 2000;39(10):1208\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"5","key":"479_CR89","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0025-6196(11)60737-4","volume":"83","author":"NK Singh","year":"2008","unstructured":"Singh NK, Nagendra S. Reversible neutrophil abnormalities related to supratherapeutic valproic acid levels. Mayo Clin Proc. 2008;83(5):600.","journal-title":"Mayo Clin Proc."},{"issue":"9","key":"479_CR90","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/BF02790401","volume":"73","author":"U Kohli","year":"2006","unstructured":"Kohli U, Gulati S. Valproate induced isolated neutropenia. Indian J Pediatr. 2006;73(9):844.","journal-title":"Indian J Pediatr."},{"issue":"2","key":"479_CR91","first-page":"130","volume":"19","author":"G Yurdaisik","year":"2002","unstructured":"Yurdaisik G, Uysal S. Valproic acid-induced neutropenia. Omu tip Dergi. 2002;19(2):130\u20132.","journal-title":"Omu tip Dergi."},{"issue":"3","key":"479_CR92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/adc.58.3.235","volume":"58","author":"DN Symon","year":"1983","unstructured":"Symon DN, Russell G. Sodium valproate and neutropenia. Arch Dis Child. 1983;58(3):235.","journal-title":"Arch Dis Child."},{"issue":"6","key":"479_CR93","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1345\/aph.1C381","volume":"37","author":"KS Vesta","year":"2003","unstructured":"Vesta KS, Medina PJ. Valproic acid-induced neutropenia. Ann Pharmacother. 2003;37(6):819\u201321.","journal-title":"Ann Pharmacother."},{"issue":"5","key":"479_CR94","first-page":"345","volume":"109","author":"S Chakraborty","year":"2011","unstructured":"Chakraborty S, Chakraborty J, Mandal S, Ghosal MK. A rare occurrence of isolated neutropenia with valproic acid: a case report. J Indian Med Assoc. 2011;109(5):345\u20136.","journal-title":"J Indian Med Assoc."},{"issue":"10","key":"479_CR95","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1345\/aph.1L239","volume":"42","author":"SC Stoner","year":"2008","unstructured":"Stoner SC, Deal E, Lurk JT. Delayed-onset neutropenia with divalproex sodium. Ann Pharmacother. 2008;42(10):1507\u201310.","journal-title":"Ann Pharmacother."},{"issue":"6","key":"479_CR96","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4088\/JCP.v66n0621c","volume":"66","author":"BJ Chae","year":"2005","unstructured":"Chae BJ, Kang BJ. A case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid. J Clin Psychiatry. 2005;66(6):801\u20132.","journal-title":"J Clin Psychiatry."},{"issue":"8751","key":"479_CR97","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0140-6736(91)92902-E","volume":"337","author":"IS Kaya","year":"1991","unstructured":"Kaya IS, Dilmen U, Toppare M, Senses DA, Prentice HG. Valproic-acid-induced pancytopenia and Coombs test positivity. Lancet. 1991;337(8751):1227\u20138.","journal-title":"Lancet."},{"issue":"2","key":"479_CR98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1532-5415.1995.tb06392.x","volume":"43","author":"D Robinson","year":"1995","unstructured":"Robinson D, Langer A, Casso D, Fenn H, Yesavage J. Pancytopenia and valproic acid\u2013a possible association. J Am Geriatr Soc. 1995;43(2):198.","journal-title":"J Am Geriatr Soc."},{"issue":"5","key":"479_CR99","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.amjopharm.2011.09.003","volume":"9","author":"JT Stewart","year":"2011","unstructured":"Stewart JT. Successful reintroduction of valproic acid after the occurrence of pancytopenia. Am J Geriatr Pharmacother. 2011;9(5):351\u20133.","journal-title":"Am J Geriatr Pharmacother."},{"issue":"3","key":"479_CR100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1532-5415.2000.tb02668.x","volume":"48","author":"OJ Oluboka","year":"2000","unstructured":"Oluboka OJ, Haslam D, Gardner DM. Pancytopenia and valproic acid: a dose-related association. J Am Geriatr Soc. 2000;48(3):349\u201350.","journal-title":"J Am Geriatr Soc."},{"issue":"5","key":"479_CR101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eurger.2016.07.006","volume":"7","author":"L Godaert","year":"2016","unstructured":"Godaert L, Saint-Albin LA, Bousquet L, Fanon J-L, Drame M. Macrocytic isolated anaemia as an unusual adverse effect of divalproex sodium in the elderly. Eur Geriatr Med. 2016;7(5):403\u20134.","journal-title":"Eur Geriatr Med."},{"issue":"6","key":"479_CR102","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1752-1947-6-239","volume":"10","author":"B Kaczorowska-Hac","year":"2012","unstructured":"Kaczorowska-Hac B, Matheisel A, Maciejka-Kapuscinska L, Wisniewski J, Alska A, Adamkiewicz-Drozynska E, Balcerska A, Reszczynska I. Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Rep. 2012;10(6):239.","journal-title":"J Med Case Rep."},{"issue":"1","key":"479_CR103","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1176\/appi.neuropsych.12030048","volume":"25","author":"SC Kuo","year":"2013","unstructured":"Kuo SC, Yeh YW, Chen CY, Yeh CB, Tzeng NS, Mao WC. Repeated adverse hematologic reactions associated with valproic acid use in a patient with acquired renal insufficiency. J Neuropsychiatry Clin Neurosci. 2013;25(1):E57\u20138 (Winter).","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"1","key":"479_CR104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00043426-199021000-00016","volume":"12","author":"DJ Ganick","year":"1990","unstructured":"Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid. A report of four patients. Am J Pediatr Hematol Oncol. 1990;12(1):80\u20135 (Spring).","journal-title":"Am J Pediatr Hematol Oncol."},{"issue":"7","key":"479_CR105","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1528-1167.2006.00587.x","volume":"47","author":"T Gerstner","year":"2006","unstructured":"Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, K\u00f6nig S. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47(7):1136\u201343.","journal-title":"Epilepsia."},{"issue":"2","key":"479_CR106","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1378\/chest.117.2.613","volume":"117","author":"C Sleiman","year":"2000","unstructured":"Sleiman C, Raffy O, Rou\u00e9 C, Mal H. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest. 2000;117(2):613.","journal-title":"Chest."},{"issue":"2","key":"479_CR107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1873-9598(09)70036-5","volume":"3","author":"H-C Hsu","year":"2009","unstructured":"Hsu H-C, Tseng H-K, Wang S-C, Wang Y-Y. Valproic acid-induced agranulocytosis. Int J Gerontol. 2009;3(2):137\u20139.","journal-title":"Int J Gerontol."},{"issue":"1","key":"479_CR108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00043426-199701000-00011","volume":"19","author":"KS Bottom","year":"1997","unstructured":"Bottom KS, Adams DM, Mann KP, Ware RE. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol. 1997;19(1):73\u20136.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"7","key":"479_CR109","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/088307380001500713","volume":"15","author":"V Farkas","year":"2000","unstructured":"Farkas V, Szab\u00f3 M, R\u00e9nyi I, Kohlh\u00e9b O, Benninger C. Temporary pure red-cell aplasia during valproate monotherapy: clinical observations and spectral electroencephalographic aspects. J Child Neurol. 2000;15(7):485\u20137.","journal-title":"J Child Neurol."},{"issue":"2","key":"479_CR110","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1371\/journal.pmed.0010051","volume":"1","author":"T The","year":"2004","unstructured":"The T, Kolla R, Dawkins F, Trouth AJ. Pure red cell aplasia after 13\u00a0years of sodium valproate, and bone marrow suppression after 17\u00a0years of carbamazepine. PLoS Med. 2004;1(2):e51.","journal-title":"PLoS Med."},{"issue":"3","key":"479_CR111","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","volume":"15","author":"SN Ahmed","year":"2006","unstructured":"Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156\u201364.","journal-title":"Seizure."},{"issue":"5","key":"479_CR112","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1528-1157.1988.tb03757.x","volume":"29","author":"D Scheffner","year":"1988","unstructured":"Scheffner D, K\u00f6nig S, Rauterberg-Ruland I, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988;29(5):530\u201342.","journal-title":"Epilepsia."},{"issue":"3","key":"479_CR113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2012.12050620","volume":"170","author":"D Vancampfort","year":"2013","unstructured":"Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, Probst M, De Hert M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265\u201374.","journal-title":"Am J Psychiatry."},{"issue":"8","key":"479_CR114","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","author":"SJ Cooper","year":"2016","unstructured":"Cooper SJ, Reynolds GP. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717\u201348.","journal-title":"J Psychopharmacol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0479-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T13:53:07Z","timestamp":1719669187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0479-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":114,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0479-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}